Profound Medical Corp.(PROF)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Profound Medical demonstrates high-value potential through its TULSA-PRO system, evidenced by gross margins consistently exceeding 60% since 2024Q2.
• However, the company's reliance on periodic capital raises to offset deep operating losses, which reached $82.5 million in 2024Q4, suggests a high-risk profile for long-term investors.
• Future success remains contingent on scaling revenue growth, which showed a 100.8% expansion in 2026Q1, while simultaneously curbing the significant SG&A expenses that currently outpace gross profit.